Clinical Trial Detail

NCT ID NCT02688712
Title ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Providence Health & Services
Indications

rectum adenocarcinoma

Therapies

Capecitabine + Galunisertib

Fluorouracil + Galunisertib

Galunisertib

Fluorouracil

Capecitabine

Age Groups: adult senior

No variant requirements are available.